- Home
- HEQ vs CNTB Comparison
HEQ vs CNTB Comparison
Compare HEQ & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HEQ | CNTB |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.4M | 128.6M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HEQ | CNTB |
|---|---|---|
| Price | $11.52 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 44.0K | ★ 317.2K |
| Earning Date | 01-01-0001 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.36 | $0.70 |
| 52 Week High | $11.72 | $3.82 |
Technical Indicators
Market Signals| Indicator | HEQ | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 42.69 |
| Support Level | $10.55 | $2.09 |
| Resistance Level | $11.65 | $2.51 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 66.13 | 19.05 |
Price Performance
Historical ComparisonAbout HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.